Added to YB: 2025-09-11
Pitch date: 2025-09-10
MBX [bearish]
MBX Biosciences, Inc.
-189.62%
current return
Author Info
No bio for this author
Company Info
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Market Cap
$1.1B
Pitch Price
$10.31
Price Target
5.00 (-83%)
Dividend
N/A
EV/EBITDA
-7.99
P/E
-10.37
EV/Sales
N/A
Sector
Pharmaceuticals
Category
N/A
MBX Biosciences (MBX): Phase 2 Trial Faces Steep Odds Against Yorvipath
MBX short: Phase 2 hypoparathyroidism trial unlikely to hit vs Yorvipath. Phase 1 showed 900ug dose couldn't sustain calcium increases like 24ug Yorvipath, endogenous PTH only dropped 30→10 vs sub-10 for Yorvipath. Weekly dosing won't reach steady state until week 4 but primary endpoint at 4 weeks. Downside to $5/share.
Read full article (7 min)